GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellular Biomedicine Group Inc (NAS:CBMG) » Definitions » EPS without NRI

Cellular Biomedicine Group (Cellular Biomedicine Group) EPS without NRI : $-2.83 (TTM As of Sep. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Cellular Biomedicine Group EPS without NRI?

Cellular Biomedicine Group's earnings per share without non-recurring items for the three months ended in Sep. 2020 was $-0.88. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2020 was $-2.83.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cellular Biomedicine Group's EPS without NRI or its related term are showing as below:

CBMG's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 4.95
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Cellular Biomedicine Group's EPS (Diluted) for the three months ended in Sep. 2020 was $-0.88. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was $-2.83.

Cellular Biomedicine Group's EPS (Basic) for the three months ended in Sep. 2020 was $-0.88. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2020 was $-2.83.


Cellular Biomedicine Group EPS without NRI Historical Data

The historical data trend for Cellular Biomedicine Group's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellular Biomedicine Group EPS without NRI Chart

Cellular Biomedicine Group Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.70 -2.09 -1.78 -2.20 -2.63

Cellular Biomedicine Group Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.82 -0.65 -0.60 -0.70 -0.88

Competitive Comparison of Cellular Biomedicine Group's EPS without NRI

For the Biotechnology subindustry, Cellular Biomedicine Group's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellular Biomedicine Group's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellular Biomedicine Group's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cellular Biomedicine Group's PE Ratio without NRI falls into.



Cellular Biomedicine Group EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellular Biomedicine Group  (NAS:CBMG) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cellular Biomedicine Group EPS without NRI Related Terms

Thank you for viewing the detailed overview of Cellular Biomedicine Group's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellular Biomedicine Group (Cellular Biomedicine Group) Business Description

Traded in Other Exchanges
N/A
Address
1345 Avenue of Americas, 15th Floor, New York, NY, USA, 10105
Cellular Biomedicine Group Inc is a biotechnology company focused on the development of proprietary cell therapies for the treatment of cancer and degenerative diseases. The company has two major cell platforms: immune cell therapy for treating a broad range of cancers using cancer vaccines, Chimeric Antigen Receptor T-cell technologies, and anti-PD-1 technologies; and human-adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases. The immuno-oncology and stem cell research team is based in both China and the United States.
Executives
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056
Pharma Ag Novartis 10 percent owner LICHTSTRASSE 35, CH-4002, BASEL V8
Edward T Schafer director 1400 31ST AVENUE SW, SUITE 60, MINOT ND 58701
Wen Tao Liu director 530 UNIVERSITY AVENUE, #17 PALO ALTO CA 94301
Terry Belmont director 530 UNIVERSITY DRIVE PALO ALTO CA 94301
Au Chun Kwok Alan director C/O CELLULAR BIOMEDICINE GROUP, INC. 530 UNIVERSITY AVENUE, #17 NEW YORK NY 94301
Hansheng Zhou director 369 LUMO ROAD HONGSHAN DISTRICT WUHAN F4 430074
Gang Jacky Ji director XIXI RONGZHUANG 27-3 JINGCHANG ROAD, YUHANG DISTRICT, HANGZHOU, ZHEJIANG F4 311100
Viktor Pan 10 percent owner HELI XI LU 183 NO. 531 SHANGHAI F4 201317
Srl Opea director VIA CESARE BATTISTA 1 MILAN L6 20122
Zheng Zhou 10 percent owner FLAT B, 25/F, TOWER 6, MARINELLA 9 WELFARE ROAD, ABERDEEN HONG KONG K3 00000
Sailing Capital Overseas Investments Fund, Lp 10 percent owner C/O UNIT 2006-08, 20F HARBOUR CENTRE 25 HARBOUR ROAD WAN CHAI K3 00000
Maplebrook Ltd 10 percent owner P.O. BOX 31119 GRAND PAVILLION HIBISCUS WAY, 802 WEST BAY ROAD GRAND CAYMAN E9 KY1-1205
Tf Venture Capital Management Co., Ltd. 10 percent owner PO BOX 472, 2ND FLOOR, HARBOUR PLACE 103 SOUTH CHURCH STREET, GEORGE TOWN GRAND CAYMAN E9 KY1-1106
Winsor Capital Ltd 10 percent owner TRINITY CHAMBERS PO BOX 4301, ROAD TOWN TORTOLA D8 00000

Cellular Biomedicine Group (Cellular Biomedicine Group) Headlines